Listed

KORU Medical Systems, Inc.: Form 10-Q for the period ended Jun 30, 2022

Filed with the SEC on Aug 3, 2022 and accepted by EDGAR at Aug 3, 2022, 16:29 ET.

Share

Controls and procedures

As filed, 1,345 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company’s management, including the Company’s Principal Executive Officer and Principal Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures as such is defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based upon their evaluations, the Principal Executive Officer and Principal Financial Officer concluded that, as of the end of the period covered by this report, the Company’s disclosure controls and procedures were effective for the purpose of ensuring that the information required to be disclosed in the reports that the Company files or submits under the Exchange Act with the Securities and Exchange Commission (the “SEC”) (1) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (2) is accumulated and communicated to the Company’s management, including its Principal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

There have been no changes in the Company’s internal control over financial reporting during the three months ended June 30, 2022, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Risk factors

As filed, 1,085 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Our operations and financial results are subject to various risks and uncertainties, including those described in “PART 1, ITEM 1A. RISK FACTORS” in our Annual Report on Form 10-K for the year ended December 31, 2021 and below in this Quarterly Report on Form 10-Q, which could adversely affect our business, financial condition, results of operations, cash flows, and the trading price of our common stock.

- 22 -

Rising inflation may materially impact our financial operations or results of operations.

Inflation has increased in the first half of 2022 and is expected to continue to increase for the near future. Inflationary factors, such as increases in the cost of our raw materials, manufacturing, interest rates, labor and overhead costs may adversely affect our operating results. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, we expect to experience effects beginning in the second half of 2022, which could have a material impact on our financial condition or results of operations.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2022-04-01 to 2022-06-30$6.5mus-gaap:Revenues
Revenue6 months2022-01-01 to 2022-06-30$12.8mus-gaap:Revenues
Cost of revenue3 months2022-04-01 to 2022-06-30$3.2mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue6 months2022-01-01 to 2022-06-30$5.8mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2022-04-01 to 2022-06-30$3.3mus-gaap:GrossProfit
Gross profit6 months2022-01-01 to 2022-06-30$7.0mus-gaap:GrossProfit
Research and development3 months2022-04-01 to 2022-06-30$1.3mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2022-01-01 to 2022-06-30$2.5mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2022-04-01 to 2022-06-30$5.5mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2022-01-01 to 2022-06-30$11.0mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2022-04-01 to 2022-06-30−$3.6mus-gaap:OperatingIncomeLoss
Operating income6 months2022-01-01 to 2022-06-30−$6.7mus-gaap:OperatingIncomeLoss
Income tax3 months2022-04-01 to 2022-06-30−$710.3kus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2022-01-01 to 2022-06-30−$1.3mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2022-04-01 to 2022-06-30−$2.9mus-gaap:NetIncomeLoss
Net income6 months2022-01-01 to 2022-06-30−$5.5mus-gaap:NetIncomeLoss
Diluted EPS3 months2022-04-01 to 2022-06-30−$0.07us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2022-01-01 to 2022-06-30−$0.12us-gaap:EarningsPerShareDiluted
Basic EPS3 months2022-04-01 to 2022-06-30−$0.07us-gaap:EarningsPerShareBasic
Basic EPS6 months2022-01-01 to 2022-06-30−$0.12us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2022-04-01 to 2022-06-3044,921,870 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2022-01-01 to 2022-06-3044,795,625 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2022-01-01 to 2022-06-30−$4.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2022-01-01 to 2022-06-30$1.9mus-gaap:PaymentsToAcquireProductiveAssets
Cash and equivalentsAt period end2022-06-30$18.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-06-30$31.0mus-gaap:AssetsCurrent
Total assetsAt period end2022-06-30$42.5mus-gaap:Assets
Current liabilitiesAt period end2022-06-30$5.7mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-06-30$9.8mus-gaap:Liabilities
Shareholders' equityAt period end2022-06-30$32.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001161697-22-000377. Last ingested by Listed: Nov 11, 2026, 02:24 ET. Listed shows no prices and gives no investment advice.